NXTC · NextCure, Inc.
$4.98
+0.26 (+5.51%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$21.61M
Shares
4.58M
Volume · Oct 23
48.55K
Avg daily vol (3M)
189.6K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.98
Open$4.96
Day$4.53–5.28
52W close$1.60–14.27
Avg vol 30d91K
Short int213K · 4.7% float · 1.9d
Short vol51%
Last earningsMar 4, 2021
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$27.37M
Trailing 12 months
Net income (TTM)
−$42.75M
Trailing 12 months
Revenue growth YoY
+1,549.1%
Year over year
Operating margin
-184.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+123.6%
Year over year · more shares
Price change (1Y)
-47.7%
Trailing year
Short interest
4.7%
Latest settlement · 1.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
−20%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
27%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−44%
trailing
YTD return
−65%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
1 of 30 funds reported for Sep 30 · net +980 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.66% of float · ▲ +102.7% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
30 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+253%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-50.1M
Balance sheet
$29.3M
net cash
Quant / Vol
risk profile
Volatility
239%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
16.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
1 of 30 funds reported for Sep 30 · net +980 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.66% of float · ▲ +102.7% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
30 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $5 · 27%
Range high $14
vs 200-day avg -38%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NXTC
this stock
NextCure, Inc.
|
$21.61M | -64.9% | +252.6% | — | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$133.55B | +15.6% | +46.2% | 30.7 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.33B | +4.3% | +20.8% | 20.3 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.90B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$65.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NXTC | -20.2% | -2.0% | -44.2% | -0.6% | -64.9% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -19.8% | -0.5% | -50.0% | -0.3% | -76.4% |